PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

Autor: Franck Morschhauser, S.-P. Yeh, G. Rossi, T. Manley, Anne Lennard, E. Domingo-Domenech, Andreas Hüttmann, T. Illidge, M. Little, M. Fanale, S. Yuen, K. Tsukasaki, K.J. Savage, Kensei Tobinai, Swami P. Iyer, T. Feldman, W. Seog Kim, S. Horwitz, Shangbang Rao, Pier Luigi Zinzani, B. Pro, A. Illes, N.L. Bartlett, L. Trümper, D. Belada, Andrei R. Shustov, Owen A. O'Connor, R. Advani, J.H. Christensen

Publikováno v: HemaSphere. 3:484-485

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d23bc14f40047d593fc9e4d687cc3d3
https://doi.org/10.1097/01.hs9.0000562572.63485.4f

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.

Autor: Yoon N; Departments of Pathology, The Catholic University of Korea Incheon St. Mary's Hospital, Incheon, Korea., Ahn S; Departments of Patholgy, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, Korea., Yong Yoo H; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea., Jin Kim S; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Seog Kim W; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Hyeh Ko Y; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Publikováno v: Oncotarget [Oncotarget] 2017 Mar 28; Vol. 8 (13), pp. 22014-22022.